Paraventricular nucleus neuropeptide expression in Huntington's disease patients

Brain Pathology

Volumn 22, Issue 5, 2012, Pages 654-661

  Van Wamelen, Daniel J ^a,b   Aziz, N Ahmad ^b   Anink, Jasper J ^a   Roos, Raymund A C ^b   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cocaine and amphetamine regulated transcript; corticotropin releasing hormone; Huntington's disease; hypothalamus; paraventricular nucleus; thyrotropin releasing hormone

Indexed keywords

ARGIPRESSIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; MESSENGER RNA; NEUROPEPTIDE; OXYTOCIN; PROTIRELIN;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN NERVE CELL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; NEUROPEPTIDES; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 84865450413     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00565.x     Document Type: Article

References (38)

1. Alkemade A, Unmehopa UA, Wiersinga WM, Swaab DF, Fliers E, (2005) Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab 90: 323-327. (Pubitemid 40116675)
2. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, et al, (2002) Autonomic nervous system function in Huntington's disease. J Neurol Neurosurg Psychiatry 72: 726-731. (Pubitemid 34557013)
3. Aziz NA, Swaab DF, Pijl H, Roos RA, (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 18: 223-251.
4. Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S, et al, (2008) Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 18: 474-483.
5. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RA, (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol 17: 1068-1074.
6. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA, (2011) Altered thyrotropic and lactotropic axes regulation in Huntington's disease. Clin Endocrinol (Oxf) 73: 540-545.
7. Bao AM, Swaab DF, (2007) Gender difference in age-related number of corticotropin-releasing hormone-expressing neurons in the human hypothalamic paraventricular nucleus and the role of sex hormones. Neuroendocrinology 85: 27-36. (Pubitemid 46550023)
8. Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, et al, (2006) Progressive alterations in the hypothalamic-pituitary- adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet 15: 1713-1721. (Pubitemid 43904837)
9. Buijs RM, Wortel J, van Heerikhuize JJ, Feenstra MG, Ter Horst GJ, Romijn HJ, Kalsbeek A, (1999) Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur J Neurosci 11: 1535-1544. (Pubitemid 29192228)
10. Coote JH, Yang Z, Pyner S, Deering J, (1998) Control of sympathetic outflows by the hypothalamic paraventricular nucleus. Clin Exp Pharmacol Physiol 25: 461-463. (Pubitemid 28298571)
11. Den Heijer JC, Bollen WL, Reulen JP, van Dijk JG, Kramer CG, Roos RA, Buruma OJ, (1988) Autonomic nervous function in Huntington's disease. Arch Neurol 45: 309-312. (Pubitemid 18081696)
12. Dong W, Seidel B, Marcinkiewicz M, Chrétien M, Seidah NG, Day R, (1997) Cellular localization of the prohormone convertases in the hypothalamic paraventricular and supraoptic nuclei: selective regulation of PC1 in corticotrophin-releasing hormone parvocellular neurons mediated by glucocorticoids. J Neurosci 17: 563-575. (Pubitemid 27024569)
13. Engeland WC, Arnhold MM, (2005) Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine 28: 325-332.
14. Fekete C, Lechan RM, (2006) Neuroendocrine implications for the association between cocaine- and amphetamine regulated transcript (CART) and hypophysiotropic thyrotropin-releasing hormone (TRH). Peptides 27: 2012-2018. (Pubitemid 44067295)
15. Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, et al, (2010) Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 120: 777-788.
16. Goldstone AP, Unmehopa UA, Swaab DF, (2003) Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity. Clin Endocrinol (Oxf) 58: 743-755. (Pubitemid 36702735)
17. Goncharuk VD, Van Heerikhuize J, Swaab DF, Buijs RM, (2002) Paraventricular nucleus of the human hypothalamus in primary hypertension: activation of corticotropin-releasing hormone neurons. J Comp Neurol 443: 321-331. (Pubitemid 34101316)
18. Goncharuk VD, Buijs RM, Swaab DF, (2007) Corticotropin-releasing hormone neurons in hypertensive patients are activated in the hypothalamus but not in the brainstem. J Comp Neurol 503: 148-168. (Pubitemid 47024424)
19. Goncharuk VD, Buijs RM, Jhamandas JH, Swaab DF, (2011) Vasopressin (VP) and neuropeptide FF (NPFF) systems in the normal and hypertensive human brainstem. J Comp Neurol 519: 93-124.
20. Heuser IJ, Chase TN, Mouradian MM, (1991) The limbic-hypothalamic- pituitary-adrenal axis in Huntington's disease. Biol Psychiatry 30: 943-952.
21. Kobal J, Meglic B, Mesec A, Peterlin B, (2004) Early sympathetic hyperactivity in Huntington's disease. Eur J Neurol 11: 842-848. (Pubitemid 39665063)
22. Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, et al, (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 93: 641-653. (Pubitemid 40617624)
23. Kurlan R, Caine E, Rubin A, Nemeroff CB, Bissette G, Zaczek R, et al, (1988) Cerebrospinal fluid correlates of depression in Huntington's disease. Arch Neurol 45: 881-883.
24. Leblhuber F, Peichl M, Neubauer C, Reisecker F, Steinparz FX, Windhager E, Maschek W, (1995) Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J Neurol Sci 132: 76-79.
25. Liu CQ, Shan L, Balesar R, Luchetti S, van Heerikhuize JJ, Luo JH, et al, (2010) A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. Methods 52: 359-366.
26. Liu X, Jin Y, Zheng H, Chen G, Tan B, Wu B, (2000) Arginine vasopressin gene expression in supraoptic nucleus and paraventricular nucleus of hypothalamous following cerebral ischemia and reperfusion. Chin Med Sci J 15: 157-161.
27. Nillni EA, (2010) Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 31: 134-156.
28. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF, (1996) Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53: 137-143. (Pubitemid 26050037)
29. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, et al, (2009) Neuroendocrine disturbances in Huntington's disease. PLoS ONE 4: e4962.
30. Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J, (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56: 1248-1252. (Pubitemid 29473217)
31. Swaab DF, (2003) The human hypothalamus: basic and clinical aspects, part I: nuclei of the human hypothalamus. In: Handbook of Clinical Neurology., MJ Aminoff, F Boller, DF Swaab, (eds), pp. 1-476. Elsevier: Amsterdam.
32. van der Sluis PJ, Pool CW, Sluiter AA, (1987) Press-blotting on gelatin-coated nitrocellulose membranes. A method for sensitive quantitative immunodetection of peptides after gel isoelectric focusing. J Immunol Methods 104: 65-71. (Pubitemid 17165815)
33. van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RA, van der Mast RC, (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J Clin Psychiatry 69: 1804-1810.
34. van Oers JW, Tilders JH, Berkenbosch F, (1989) Characterization and biological activity of a rat monoclonal antibody to rat/human corticotropin-releasing factor. Endocrinology 124: 1239-1246. (Pubitemid 19082691)
35. van Wamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, Swaab DF, (2011) Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol 21: 419-427.
36. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr, (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577. (Pubitemid 16196286)
37. Zhou JN, Hofman MA, Swaab DF, (1996) Morphometric analysis of vasopressin and vasoactive intestinal polypeptide neurons in the human suprachiasmatic nucleus: influence of microwave treatment. Brain Res 742: 334-338. (Pubitemid 27016040)
38. Zhou JN, Riemersma RF, Unmehopa UA, Hoogendijk WJ, van Heerikhuize JJ, Hofman MA, Swaab DF, (2001) Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 58: 655-662. (Pubitemid 32640861)